Compositions and methods for viral sensitization
US-2024360115-A1 · Oct 31, 2024 · US
Clostridium perfringens bacteriophage Clo-PEP-2 and use for inhibiting Clostridium perfringens proliferation of same
US11529406B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11529406-B2 |
| Application number | US-201816487511-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 11, 2018 |
| Priority date | Feb 24, 2017 |
| Publication date | Dec 20, 2022 |
| Grant date | Dec 20, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to Siphoviridae bacteriophage Clo-PEP-2 (accession number KCTC 13185BP), separated from nature, which is capable of killing Clostridium perfringens and has a genome expressed by sequence number 1 and a method for preventing or treating diseases, induced by Clostridium perfringens, by means of a composition comprising the Siphoviridae bacteriophage Clo-PEP-2 as an active ingredient.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of preventing or treating a disease caused by Clostridium perfringens , the method comprising: administering to an animal other than a human a composition comprising an effective amount of Siphoviridae bacteriophage Clo-PEP-2 having a genome set forth in SEQ ID NO: 1 and deposited under the accession number of KCTC 13185BP, which has an ability to kill Clostridium perfringens.
Assignees
Inventors
Classifications
- C12N7/00Primary
Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title
- A23K10/18Primary
of live microorganisms · CPC title
Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions (A23K10/12 takes precedence) · CPC title
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title
Viruses; Subviral particles; Bacteriophages · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11529406B2 cover?
- The present invention relates to Siphoviridae bacteriophage Clo-PEP-2 (accession number KCTC 13185BP), separated from nature, which is capable of killing Clostridium perfringens and has a genome expressed by sequence number 1 and a method for preventing or treating diseases, induced by Clostridium perfringens, by means of a composition comprising the Siphoviridae bacteriophage Clo-PEP-2 as an a…
- Who is the assignee on this patent?
- Intron Biotechnology Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N7/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).